Ipamorelin — Selective Growth Hormone Secretagogue

Discovery and Origin

Ipamorelin emerged from a systematic medicinal chemistry programme at Novo Nordisk during the mid-1990s, when researchers were actively hunting for growth hormone secretagogues that retained efficacy while shedding the off-target hormonal effects seen in earlier compounds. The landmark characterisation was published in 1998 by Raun, Hansen, Johansen and colleagues, who described ipamorelin — internally designated NNC 26-0161 — as the first truly selective growth hormone secretagogue [PMID:9849822].

The team synthesised a library of pentapeptide analogues built around the core structure Aib-His-D-2-Nal-D-Phe-Lys-NH2 and screened each for potency at the pituitary level alongside its propensity to drive unwanted hormone release. Most earlier GH-releasing peptides (GHRPs) such as GHRP-2 and GHRP-6, while effective at provoking GH pulses, also produced measurable increases in cortisol, prolactin and adrenocorticotrophic hormone (ACTH). Ipamorelin stood apart: at equimolar doses it matched or exceeded the GH-releasing potency of its predecessors but displayed a dramatically cleaner side-effect profile in both rat and porcine models [PMID:9849822].

This publication effectively redefined what selectivity could mean for a growth hormone secretagogue and positioned ipamorelin as a reference molecule for the class — a status it still holds in the research community nearly three decades later.

Mechanism of Action

Ipamorelin is a synthetic agonist of the ghrelin receptor, formally designated GHSR-1a (Growth Hormone Secretagogue Receptor subtype 1a). GHSR-1a is expressed most densely in the anterior pituitary, hypothalamus, hippocampus, and scattered peripheral tissues. When ipamorelin binds the receptor, it triggers a Gαq/11-coupled intracellular cascade that raises intracellular calcium and inositol phosphate, ultimately depolarising somatotroph cells in the pituitary and causing a burst of GH secretion into the portal circulation [PMID:9849822].

The critical mechanistic distinction from first-generation GHRPs lies in receptor selectivity at the hypothalamic-pituitary-adrenal (HPA) axis. GHRP-6 and GHRP-2 activate corticotroph pathways with sufficient potency to raise plasma cortisol and ACTH by clinically relevant margins. Ipamorelin shows negligible activity at these same pathways [PMID:10373343]. Similarly, prolactin — another common off-target in older secretagogues — remains essentially unchanged after ipamorelin administration in well-controlled animal studies. The selectivity profile is maintained across a wide dose range, which is unusual; many compounds show clean profiles at low doses but lose selectivity as concentrations rise.

Ipamorelin's GH pulses are pulsatile rather than supraphysiological: the peptide amplifies the natural rhythmic bursts that the somatotroph axis already generates rather than flooding the system continuously. This pulsatile pattern matters because continuous or tonically elevated GH tends to downregulate receptors and blunt downstream IGF-1 signalling — effects that periodic pulses avoid.

It is also worth noting that ipamorelin does not significantly stimulate ghrelin's appetite-promoting pathway in rodent feeding studies at GH-releasing doses, distinguishing it from native ghrelin and from GHRP-6, which reliably increases hunger.

Researched Applications

The bulk of published research on ipamorelin is confined to animal models and early-phase human pharmacokinetic studies. In rat models of GH deficiency, subcutaneous ipamorelin restored IGF-1 concentrations toward normal and improved lean mass accrual over multi-week dosing periods without the cortisol elevations seen with comparator GHRPs.

A particularly important line of investigation concerns the combination of ipamorelin with GHRH analogues. GHRH acts on a separate receptor on somatotrophs to prime the cell for secretion, while GHSR-1a agonists provide a distinct triggering stimulus. When both pathways are activated simultaneously, the resulting GH pulse is markedly larger than either agent produces alone — a synergy documented for ipamorelin paired with modified GHRH peptides including CJC-1295 [Alba et al., 2006]. This combination approach has become a dominant strategy in research protocols targeting robust GH axis stimulation, because individual agents at moderate doses can be combined to achieve additive or supra-additive GH release.

In Sondergaard's clinical pharmacodynamic work, ipamorelin produced measurable increases in overnight GH secretory mass in GH-deficient adult volunteers, validating that the receptor pharmacology seen in animal studies translates to human pituitary biology.

Preclinical investigations have also examined ipamorelin's potential in bone metabolism, gut motility (GHSR-1a is expressed in enteric neurons), and post-surgical recovery contexts, though none of these indications have advanced to regulatory clinical development.

Dosing in Research Contexts

In published preclinical and early human pharmacokinetic studies, ipamorelin has been administered subcutaneously at doses ranging from approximately 200 µg to 300 µg per injection. Experimental protocols frequently use three daily administrations to exploit the peptide's short half-life of approximately two hours and to approximate the physiological pattern of episodic GH secretion.

Gobburu and colleagues modelled the pharmacokinetics and pharmacodynamics of single-dose ipamorelin in human volunteers and found that GH peak concentrations were dose-dependent and reached maximum approximately fifteen to thirty minutes post-injection, returning toward baseline within approximately three hours — consistent with the receptor-mediated, pulsatile mechanism described above.

When studied in combination with CJC-1295 (no-DAC variant, also called modified GRF 1-29), ipamorelin is typically co-administered at the same injection site, leveraging the complementary receptor mechanisms described in the section above. The no-DAC form of CJC-1295 carries a half-life of approximately thirty minutes, making it temporally compatible with ipamorelin's own kinetics.

All dosing figures in this monograph are derived from published research literature and are presented for scientific reference only. They do not constitute clinical guidance of any kind.

Safety Profile in Research

Ipamorelin's selectivity advantage translates directly into a more benign safety signal in animal studies compared to earlier GHRPs. The absence of significant cortisol, ACTH, and prolactin elevation removes the theoretical risks that accompany HPA axis activation — adrenal sensitisation, immunosuppression, and lactotrophic effects — at doses sufficient to stimulate GH release [PMID:10373343].

Injection-site tolerability in rodent studies has been acceptable, with no unusual local reactions reported at subcutaneous doses in the published literature. Acute tolerability in the Gobburu human PK study was described as good at the doses examined.

Longer-term safety in humans has not been characterised in peer-reviewed trials. Theoretical concerns applicable to any GH axis stimulant — including the possibility of promoting pre-existing neoplastic tissue, fluid retention at higher GH concentrations, and receptor desensitisation with prolonged continuous dosing — cannot be excluded based on available data.

Ipamorelin has not been evaluated in pregnant or lactating subjects, and no human dose-finding or dose-escalation studies have been registered with major clinical trial databases as of the date of this monograph.

Sigalos and Pastuszak's 2018 review of growth hormone secretagogue safety concluded that the class remains inadequately characterised for human therapeutic use, a judgement that applies to ipamorelin specifically [Sigalos & Pastuszak, 2018].

UK Regulatory Status

Ipamorelin is not licensed as a medicine in the United Kingdom. It holds no Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) and is not listed on the British National Formulary. It is not a scheduled controlled substance under the Misuse of Drugs Act 1971.

Supply of ipamorelin for human use without a valid MHRA licence is unlawful under the Human Medicines Regulations 2012. It is legally handled in the UK only as a research chemical for in vitro laboratory or non-human research purposes, subject to appropriate institutional ethics and governance approvals.

Individuals obtaining ipamorelin for self-administration do so outside any legal or medical framework. The regulatory position described here reflects the situation as of May 2026; regulations are subject to change and readers should verify the current position with the MHRA or a qualified legal adviser.

Reconstitution and Handling

Ipamorelin is supplied as a lyophilised (freeze-dried) white powder in sealed vials. Standard reconstitution practice in laboratory settings uses bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative) added slowly by directing the diluent down the interior wall of the vial to avoid foaming.

A common research preparation uses 2 mL of bacteriostatic water per 5 mg vial, yielding a concentration of 2,500 µg per mL, which simplifies volume calculations for 200–300 µg administrations. Once reconstituted, vials should be stored at between two and eight degrees Celsius and used within four weeks. Freezing reconstituted peptide is generally not recommended as repeated freeze-thaw cycles degrade peptide integrity.

Ipamorelin is sensitive to prolonged exposure to elevated temperature and direct light. Lyophilised stock retains stability for longer periods when stored at or below minus twenty degrees Celsius in a desiccated, light-protected environment.

All handling must conform to applicable laboratory safety protocols and institutional biosafety requirements.

Frequently Asked Questions

How does ipamorelin differ from GHRP-6? Both peptides bind GHSR-1a and stimulate pituitary GH release, but GHRP-6 also significantly elevates cortisol and prolactin and reliably increases appetite via central mechanisms. Ipamorelin produces equivalent or superior GH release at research doses with negligible impact on cortisol, ACTH, or prolactin [PMID:10373343], and does not drive appetite at GH-releasing doses.

Why is ipamorelin frequently combined with CJC-1295? Ipamorelin acts on GHSR-1a while CJC-1295 (modified GRF 1-29) acts on the GHRH receptor — two distinct receptors on the same pituitary somatotroph cell. Co-activation of both pathways produces synergistic GH pulse amplitude that neither agent achieves alone [Alba et al., 2006].

Is ipamorelin detectable on anti-doping tests? The World Anti-Doping Agency (WADA) prohibits GH-releasing peptides including ipamorelin under its Prohibited List. Analytical methods capable of detecting ipamorelin and its metabolites in urine have been developed by accredited anti-doping laboratories. Athletes subject to anti-doping rules should treat ipamorelin as a prohibited substance.

Does ipamorelin raise IGF-1? In animal studies, repeated dosing with ipamorelin that successfully elevated GH pulses did lead to downstream increases in hepatic and circulating IGF-1. The magnitude and duration of any IGF-1 elevation depends on dosing frequency, baseline GH axis status, and co-administration of GHRH analogues.

---

Related Stacks

Ipamorelin is a component of several research peptide stacks documented on this site:

• CJC-1295 / Ipamorelin / Tesamorelin GH Stack — A comprehensive GH axis protocol combining GHRH and GHRP activity with tesamorelin's visceral-fat research data.
• Ipamorelin / CJC-1295 / BPC-157 Recomp Stack — A repair-and-recomposition oriented research stack pairing selective GH stimulation with BPC-157's connective-tissue research profile.

---

This monograph is for scientific reference and educational purposes only. Ipamorelin is an unapproved research compound. Nothing on this page constitutes medical advice, and no information here should be used to guide human self-administration.

Source research-grade Ipamorelin

Ipamorelin — Selective Growth Hormone Secretagogue is sold for laboratory and in vitro research use only. UK regulatory status: Unapproved research compound globally. For in vitro and laboratory research only..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk